Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Peripheral T-Cell Lymphomas (PTCL) Pipeline Report 2016: Therapeutics Review Detailing 24 Companies & 31 Molecules - Research and Markets

Research and Markets
Posted on: 12 Oct 16

Research and Markets has announced the addition of the "Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2016" report to their offering.

Peripheral T-Cell Lymphomas (PTCL) pipeline therapeutics constitutes close to 31 molecules

Out of which approximately 31 molecules are developed by Companies. Our latest report Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Peripheral T-Cell Lymphomas (PTCL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Peripheral T-Cell Lymphomas (PTCL) Peripheral T-cell lymphoma (PTCL) is a rare and often aggressive (fast-growing) cancer that develops from white blood cells called T-lymphocytes, or T-cells. T-cells are an important part of the immune system; they help the body to fight infection. In cases when these cells start to grow too quickly and resist dying, they can accumulate in the body. Symptoms may include fatigue, a painless swelling in the neck, armpit or groin (due to an enlarged lymph node), night sweats and rash. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 19, 5, 4 and 1 respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Peripheral T-Cell Lymphomas (PTCL) and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Peripheral T-Cell Lymphomas Overview
  3. Therapeutics Development
  4. Pipeline Products for Peripheral T-Cell Lymphomas - Overview
  5. Pipeline Products for Peripheral T-Cell Lymphomas - Comparative Analysis
  6. Peripheral T-Cell Lymphomas - Therapeutics under Development by Companies
  7. Peripheral T-Cell Lymphomas - Therapeutics under Investigation by Universities/Institutes
  8. Peripheral T-Cell Lymphomas Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Peripheral T-Cell Lymphomas - Products under Development by Companies
  13. Peripheral T-Cell Lymphomas - Products under Investigation by Universities/Institutes
  14. Peripheral T-Cell Lymphomas - Companies Involved in Therapeutics Development
  • AB Science SA
  • Affimed GmbH
  • arGEN-X BV
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Celgene Corporation
  • CerRx, Inc.
  • Chipscreen Biosciences Ltd
  • CSPC Pharmaceutical Group Limited
  • Eisai Co., Ltd.
  • Genosco
  • Incyte Corporation
  • Japan Tobacco Inc.
  • Johnson & Johnson
  • Mundipharma International Ltd
  • Ono Pharmaceutical Co., Ltd.
  • Onxeo SA
  • Pfizer Inc.
  • Pharma Mar, S.A.
  • Portola Pharmaceuticals, Inc.
  • Rhizen Pharmaceuticals S.A.
  • Seattle Genetics, Inc.
  • Solasia Pharma K.K.
  • Spectrum Pharmaceuticals, Inc.

For more information about this report visit

View source version on

Business Wire

Last updated on: 12/10/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.